

DAYS
MATTER™



Biohaven® is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Our commitment to patients drives us to follow the path of science and motivates us to overcome the obstacles in bringing innovative medicines to those in need.

In the pursuit of our mission, we know that patients are waiting and days matter. It's why we operate with urgency and intention in applying cutting-edge science to turn breakthrough discoveries into therapies for diseases with little or no treatment options. Fueled by our entrepreneurial structure and our proven drug development capabilities, Biohaven is poised to create a healthier future for the people who count on us.

				PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	MARKET	
GLUTAMATE	Troriluzole	BHV-4157	Obsessive-Compulsive Disorder	████████████████████					
			Spinocerebellar Ataxia	████████████████████					
MYOSTATIN	Taldefgrobep Alfa	BHV-2000	Spinal Muscular Atrophy	████████████████████					
			Obesity	██████████████████					
ION CHANNEL	Kv7 Activator	BHV-7000	Focal Epilepsy	████████████████████					
			Generalized Epilepsy	████████████████████					
			Bipolar Disorder	████████████████████					
			Major Depressive Disorder	██████████████████					
	TRPM3 Antagonist	BHV-2100	Migraine	██████████████████					
			Neuropathic Pain	██████████████████					
INFLAMMATION & IMMUNOLOGY	TYK2/JAK1 Inhibitor ¹	BHV-8000	Prevention of Amyloid Therapy Induced ARIA	██████████████████					
			Early Alzheimer's Disease	██████████████████					
			Early Parkinson's Disease	██████████████████					
			Multiple Sclerosis	██████████████████					
	IgG Degradar	BHV-1300	Rheumatoid Arthritis	██████████████████					
			Myasthenia Gravis	██████████████████					
IgA Degradar	BHV-1400	IgA Nephropathy	██████████████████						
		β1-AR Degradar	BHV-1600	Dilated Cardiomyopathy	██████████████████				
ONCOLOGY	CD38	BHV-1100		Multiple Myeloma	██████████████████				
	Trop2		BHV-1510	Advanced or Metastatic Epithelial Tumors	██████████████████				
	CD30 ²			BHV-1500	Hodgkin's Lymphoma	██████████████			

1. Brain penetrant. 2. Next-gen brentuximab vedotin.
ARIA, Amyloid-related imaging abnormalities.

GLUTAMATE | Obsessive-Compulsive Disorder

Troiluzole is Biohaven's glutamate modulator currently in Phase 3 development for obsessive-compulsive disorder (OCD). It is being evaluated as an adjunctive therapy in patients with an inadequate response to existing standard-of-care treatment. In SCA, topline results from a real-world evidence protocol are expected in 2H 2024.

MYOSTATIN | Neuromuscular and Metabolic Diseases

Taldefgrobep alfa is a novel myostatin inhibitor optimized to block both myostatin and activin A signaling, two key regulators of muscle growth. Biohaven expects topline data in 2H 2024 from our global Phase 3 study of taldefgrobep in patients with spinal muscular atrophy, as an adjunctive therapy to enhance muscle mass and function in patients treated with standard-of-care treatments. Taldefgrobep also has significant promise as a potential treatment for obesity. In an ongoing Phase 1 study, taldefgrobep demonstrated a higher reduction in body weight and fat mass, and greater increase in lean muscle when used in combination with the GLP-1 agonist semaglutide versus treatment with semaglutide alone.

ION CHANNEL: Kv7 ACTIVATOR | Epilepsy, Bipolar Disorder, Depression

BHV-7000 is a selective activator of Kv7.2/7.3 potassium channels, a breakthrough target in neurology and neuropsychiatry with blockbuster potential. Biohaven is enrolling five Phase 2/3 clinical trials for BHV-7000 in refractory focal epilepsy, idiopathic generalized epilepsy, major depressive disorder, and bipolar disorder.

ION CHANNEL: TRPM3 ANTAGONIST | Migraine, Neuropathic Pain

BHV-2100 is an oral, selective TRPM3 antagonist that offers a novel, non-addictive treatment for migraine and neuropathic pain. Phase 1 study demonstrated rapid absorption, sustained concentrations, and excellent safety and tolerability; no thermoregulatory AEs as with other TRP antagonists or sedation associated with standard-of-care pain medications.

TYK2/JAK1 INHIBITOR | Neuroinflammatory Disorders

BHV-8000 is a selective, brain-penetrant TYK2/JAK1 inhibitor with the potential to treat neuroinflammatory disorders including the prevention of amyloid therapy induced ARIA, Alzheimer's disease, Parkinson's disease and multiple sclerosis where there is an underlying inflammatory component that drives neurodegeneration and disease progression.

DEGRADERS | Developing Next-Generation Therapies

Biohaven is rapidly pursuing the development of potential extracellular protein degrader candidates, initially targeting IgG, IgA, and 1-AR autoantibodies to treat common and rare antibody-mediated diseases. Our proprietary platform technologies are expected to have significant potential benefit for multiple diseases.

ONCOLOGY | Developing Next-Generation ADCs

Biohaven's ADC technology utilizes novel conjugation chemistry which has the potential to be superior to the current industry standard maleimide and lipophilic click chemistry. This unique approach has potential application to multiple payload-linker combinations, antibodies and oncologic indications.

AT A GLANCE

Employees

200+ globally

Locations

New Haven, CT
Headquarters

Cambridge, MA

Yardley, PA

Pittsburgh, PA

Dublin, Ireland

Executive Management

Vlad Coric, M.D.

Chairman and
Chief Executive Officer

Matthew Buten

Chief Financial Officer

Clifford Bechtold

President and General
Manager, Biohaven Ireland,
Chief Compliance Officer

Irfan Qureshi, M.D.

Chief Medical Officer

Bruce Car, Ph.D.

Chief Scientific Officer

Michael Bozik, M.D.

President, Ion Channel
Research and Development

Steven Dworetzky, Ph.D.

Senior Vice President, Ion
Channel Research and
Development

Nick Kozauer, M.D.

Senior Vice President,
Clinical Development
and Regulatory Strategy

Investor Relations

Jen Porcelli

+1 201-248-0741

Media Contact

Mike Beyer

+1 312-961-2502

biohaven

215 Church Street
New Haven, CT 06510